• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经导管动脉化疗栓塞术后肝细胞癌中血管内皮生长因子表达增加。

Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization.

作者信息

Wang B, Xu H, Gao Z Q, Ning H F, Sun Y Q, Cao G W

机构信息

Department of Radiology, Medical Imaging Center of Affiliated Hospital, Weifang Medical University, Weifang, PR China.

出版信息

Acta Radiol. 2008 Jun;49(5):523-9. doi: 10.1080/02841850801958890.

DOI:10.1080/02841850801958890
PMID:18568538
Abstract

BACKGROUND

Changes in the biological behavior of residual viable hepatocellular carcinoma (HCC) tissue after transcatheter arterial chemoembolization (TACE) remain unclear. Several studies have reported that TACE inhibits tumor angiogenesis and induces tumor cell apoptosis, while other studies have found that TACE stimulates tumor angiogenesis and thus increases the proliferative activity of the tumor cells to some degree.

PURPOSE

To investigate the intratumoral microvessel density (MVD) and vascular endothelial growth factor (VEGF) expression in residual surviving cancerous tissue after TACE in HCC.

MATERIAL AND METHODS

Tumor specimens from 63 histopathologically diagnosed patients were studied: 42 comprising the control group (treated by surgery alone) and 21 comprising the TACE group (those treated by TACE 1-2 times prior to surgical resection). The number of VEGF-positive cells, MVD, and microvessel diameter were measured.

RESULTS

The MVD was 51.69+/-18.17 and 58.57+/-15.75 in the control and TACE groups, respectively. There was no significant difference between the two groups (t=1.48, P>0.05). The microvessel diameter was 17.62+/-10.54 microm and 15.79+/-7.65 microm in the control and TACE groups, respectively, indicating no significant difference between the two groups (t=0.71, P>0.05). The number of VEGF-positive cells in the TACE group, i.e., 243.66+/-88.88, was higher than that in the control group, i.e., 138.26+/-65.24 (t=5.34, P<0.01). TACE increased VEGF expression in the residual surviving HCC tissues, and there was a positive correlation between VEGF expression and MVD (r=0.4936, t=4.4329, P<0.05) in the HCC tissue.

CONCLUSION

The study indicates that the residual surviving cancerous tissue in HCC after TACE has a rich vascularity. TACE increases VEGF expression in the residual surviving cancerous tissue.

摘要

背景

经导管动脉化疗栓塞术(TACE)后残余存活肝细胞癌(HCC)组织的生物学行为变化尚不清楚。一些研究报告称TACE抑制肿瘤血管生成并诱导肿瘤细胞凋亡,而其他研究发现TACE刺激肿瘤血管生成,从而在一定程度上增加肿瘤细胞的增殖活性。

目的

研究肝癌经TACE治疗后残余存活癌组织中的瘤内微血管密度(MVD)和血管内皮生长因子(VEGF)表达。

材料与方法

对63例经组织病理学诊断的患者的肿瘤标本进行研究:42例为对照组(仅接受手术治疗),21例为TACE组(手术切除前接受1 - 2次TACE治疗)。测量VEGF阳性细胞数、MVD和微血管直径。

结果

对照组和TACE组的MVD分别为51.69±18.17和58.57±15.75。两组之间无显著差异(t = 1.48,P>0.05)。对照组和TACE组的微血管直径分别为17.62±10.54微米和15.79±7.65微米,表明两组之间无显著差异(t = 0.71,P>0.05)。TACE组VEGF阳性细胞数为243.66±88.88,高于对照组的138.26±65.24(t = 5.34,P<0.01)。TACE增加了残余存活肝癌组织中的VEGF表达,且肝癌组织中VEGF表达与MVD之间存在正相关(r = 0.4936,t = 4.4329,P<0.05)。

结论

该研究表明肝癌经TACE治疗后残余存活癌组织血管丰富。TACE增加了残余存活癌组织中的VEGF表达。

相似文献

1
Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization.经导管动脉化疗栓塞术后肝细胞癌中血管内皮生长因子表达增加。
Acta Radiol. 2008 Jun;49(5):523-9. doi: 10.1080/02841850801958890.
2
[Intratumoral microvessel density and expression of vascular endothelial growth factor in hepatocellular carcinoma after chemoembolization].化疗栓塞后肝细胞癌瘤内微血管密度及血管内皮生长因子表达
Zhonghua Gan Zang Bing Za Zhi. 2002 Jun;10(3):170-3.
3
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.经动脉化疗栓塞术(TACE)在肝细胞癌(HCC)中的应用:血管生成与侵袭性的作用
Am J Gastroenterol. 2008 Apr;103(4):914-21. doi: 10.1111/j.1572-0241.2007.01712.x. Epub 2008 Jan 2.
4
Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma.人肝细胞癌中血管内皮生长因子、微血管密度的定量分析及其临床病理特征
Hepatobiliary Pancreat Dis Int. 2005 May;4(2):220-6.
5
Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.微血管密度和血管内皮生长因子表达在肝细胞癌及周围肝组织中的临床意义:血管内皮生长因子可能参与肝硬化肝脏的血管生成
Hepatology. 1998 Jun;27(6):1554-62. doi: 10.1002/hep.510270613.
6
[Expressions of inducible nitric oxide synthase and vascular endothelial growth factor and their relationship with microvessel density in hepatocellular carcinoma].[诱导型一氧化氮合酶和血管内皮生长因子在肝癌中的表达及其与微血管密度的关系]
Ai Zheng. 2005 Jan;24(1):99-103.
7
Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.经导管动脉化疗栓塞治疗的肝细胞癌肝硬化患者的血清 VEGF-A、血管生成素-2 和内皮抑素的连续测量。
Kaohsiung J Med Sci. 2011 Aug;27(8):314-22. doi: 10.1016/j.kjms.2011.03.008. Epub 2011 May 8.
8
The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE).多柔比星对经动脉化疗栓塞术(TACE)后肝细胞癌患者血清血管内皮生长因子(VEGF)变化的影响。
J Med Assoc Thai. 2008 Oct;91(10):1539-43.
9
[Relation between vascular endothelial growth factor and reoccurence-metastasis after transcatheter arterial chemoembolization in hepatocellar carcinoma].[肝细胞癌经动脉化疗栓塞术后血管内皮生长因子与复发转移的关系]
Zhonghua Zhong Liu Za Zhi. 2003 Nov;25(6):562-5.
10
[Expression and prognostic value of proliferating cell nuclear antigen in hepatocellular carcinoma patients received preoperative transcatheter arterial chemoembolization].[增殖细胞核抗原在接受术前经动脉化疗栓塞的肝细胞癌患者中的表达及预后价值]
Ai Zheng. 2008 Feb;27(2):201-5.

引用本文的文献

1
Angiogenetic Factors in Hepatocellular Carcinoma During Transarterial Chemoembolization: A Pilot Study.经动脉化疗栓塞期间肝细胞癌中的血管生成因子:一项初步研究。
Cancers (Basel). 2025 Aug 13;17(16):2642. doi: 10.3390/cancers17162642.
2
Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis.乐伐替尼联合经动脉化疗栓塞术(伴或不伴程序性死亡-1抑制剂)治疗中晚期肝细胞癌的疗效和安全性:一项系统评价和荟萃分析
Front Immunol. 2025 Jul 24;16:1586914. doi: 10.3389/fimmu.2025.1586914. eCollection 2025.
3
Efficacy and safety of transcatheter arterial embolization combined with ablation and regorafenib for unresectable hepatocellular carcinoma patients failing first-line treatment: a real-world study.
经动脉导管栓塞联合消融及瑞戈非尼治疗一线治疗失败的不可切除肝细胞癌患者的疗效与安全性:一项真实世界研究
J Gastrointest Oncol. 2025 Jun 30;16(3):1050-1059. doi: 10.21037/jgo-2025-337. Epub 2025 Jun 27.
4
Comparison analysis of different doses bevacizumab plus ICIs and interventional therapy in unresectable hepatocellular carcinoma: a real-world study.不同剂量贝伐单抗联合免疫检查点抑制剂及介入治疗不可切除肝细胞癌的比较分析:一项真实世界研究
J Gastrointest Oncol. 2025 Jun 30;16(3):1196-1207. doi: 10.21037/jgo-2024-962. Epub 2025 Jun 25.
5
Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.经动脉化疗栓塞联合酪氨酸激酶抑制剂治疗肝细胞癌的疗效:一项系统评价与Meta分析
Cancers (Basel). 2025 Jun 24;17(13):2110. doi: 10.3390/cancers17132110.
6
Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.经动脉化疗栓塞术联合阿帕替尼治疗不可切除肝细胞癌:一项多中心、随机、开放标签的III期试验
BMC Med. 2025 May 28;23(1):313. doi: 10.1186/s12916-025-04159-y.
7
Transarterial Chemoembolization for Hepatocellular Carcinoma: Current Role and Techniques.经动脉化疗栓塞治疗肝细胞癌:当前的作用和技术
Interv Radiol (Higashimatsuyama). 2024 Oct 4;10:e20240016. doi: 10.22575/interventionalradiology.2024-0016. eCollection 2025 Mar 28.
8
Anticancer effects of vitamin K combined with transarterial chemoembolization in hepatocellular carcinoma, a randomized controlled trial.维生素K联合经动脉化疗栓塞术治疗肝细胞癌的抗癌作用:一项随机对照试验
Br J Cancer. 2025 Apr 22. doi: 10.1038/s41416-025-03022-4.
9
Hepatocellular carcinoma recurrence: Predictors and management.肝细胞癌复发:预测因素与管理
Liver Res. 2023 Nov 19;7(4):321-332. doi: 10.1016/j.livres.2023.11.004. eCollection 2023 Dec.
10
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.度伐利尤单抗联合或不联合贝伐单抗与经动脉化疗栓塞术治疗肝细胞癌(EMERALD-1):一项多区域、随机、双盲、安慰剂对照的3期研究。
Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8.